Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters

Recruiting Phase 3 Interventional Study
Venous Thromboembolism Cancer
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Prevention
Participants needed
1,828 (estimated)
Sponsor
Ottawa Hospital Research Institute · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The purpose of the full trial is to determine the efficacy and safety of prophylactic dose rivaroxaban to prevent VTE among cancer patients with CVC.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients 18 years of age or older with a new or existing diagnosis of cancer and a CVC inserted in the last 72 hours. Exclusion criteria: 1. CVC in place for \>72 hours 2. Patient requires anticoagulation for other indications 3. Concomitant use of dual antiplatelet therapy …
Contacts

Bashour Yazji

613-737-8899

byazji@ohri.ca

CONTACT